Loading...
•
Jun 30, 2022
STERIS Q1 2023 Earnings Report
STERIS's financial performance for Q1 2023 reflected solid revenue growth and strong demand despite supply chain challenges.
Key Takeaways
STERIS announced a 19% increase in revenue, reaching $1.2 billion. Constant currency organic revenue grew by 6%. The company reported an EPS of $1.10 and an adjusted EPS of $1.90.
Revenue increased by 19% as reported, with a 6% constant currency organic growth.
Reported EPS was $1.10, while adjusted EPS reached $1.90.
Healthcare revenue grew by 16% to $698.5 million.
Free cash flow increased to $117.1 million.
Revenue by Segment
Revenue by Geographic Location
Forward Guidance
For fiscal year 2023, STERIS anticipates constant currency organic revenue growth of approximately 10%. As reported revenue is expected to increase approximately 9%. Adjusted earnings per diluted share are now anticipated to be in the range of $8.40 to $8.60.
Positive Outlook
- Constant currency organic revenue growth is anticipated to be approximately 10%.
- As reported revenue is expected to increase approximately 9%.
- Adjusted earnings per diluted share are anticipated to be in the range of $8.40 to $8.60.
- Demand for our products remains strong.
- Significant backlog in Healthcare capital equipment.
Challenges Ahead
- Ongoing supply chain challenges.
- Procedure volumes somewhat lighter than anticipated.
- Approximately $100 million in anticipated negative impact of foreign currency fluctuations on as reported revenue.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...